checkAd
    Startseite > Aktien > Fractyl Health > Nachrichten
    Fractyl Health Aktie
    6,7400
     
    USD
    +0,30 %
    +0,0200 USD
    Letzter Kurs 01.06.24 Nasdaq
    6,7300
     
    USD
    100 STK
    Geldkurs 31.05.24
    6,7600
     
    USD
    200 STK
    Briefkurs 31.05.24
    ISIN: US35168W1036 · SYM: GUTS · USA

    Neueste Nachrichten

    Fractyl Health to Present New Preclinical Obesity Data from Rejuva Platform at the American Diabetes Association’s 84th Scientific Sessions
    29.05.24 · globenewswire · Fractyl Health
    Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024
    20.05.24 · globenewswire · Fractyl Health
    Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
    13.05.24 · globenewswire · Fractyl Health
    Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
    13.05.24 · globenewswire · Fractyl Health
    Fractyl Health to Present at BofA Securities 2024 Health Care Conference
    08.05.24 · globenewswire · Fractyl Health
    Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
    07.05.24 · globenewswire · Fractyl Health
    Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
    30.04.24 · globenewswire · Fractyl Health
    Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
    02.04.24 · globenewswire · Fractyl Health
    Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    01.04.24 · globenewswire · Fractyl Health
    Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
    01.04.24 · globenewswire · Fractyl Health
    UPDATE -- Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
    12.03.24 · globenewswire · Fractyl Health
    Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
    12.03.24 · globenewswire · Fractyl Health